These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29144890)

  • 21. Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level.
    Nishimura H; Enokida H; Sakamoto T; Takahashi T; Hayami H; Nakagawa M
    J Artif Organs; 2018 Sep; 21(3):378-382. PubMed ID: 29675599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
    Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
    Jarius S; Ruprecht K; Wildemann B; Kuempfel T; Ringelstein M; Geis C; Kleiter I; Kleinschnitz C; Berthele A; Brettschneider J; Hellwig K; Hemmer B; Linker RA; Lauda F; Mayer CA; Tumani H; Melms A; Trebst C; Stangel M; Marziniak M; Hoffmann F; Schippling S; Faiss JH; Neuhaus O; Ettrich B; Zentner C; Guthke K; Hofstadt-van Oy U; Reuss R; Pellkofer H; Ziemann U; Kern P; Wandinger KP; Bergh FT; Boettcher T; Langel S; Liebetrau M; Rommer PS; Niehaus S; Münch C; Winkelmann A; Zettl U UK; Metz I; Veauthier C; Sieb JP; Wilke C; Hartung HP; Aktas O; Paul F
    J Neuroinflammation; 2012 Jan; 9():14. PubMed ID: 22260418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
    Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.
    Mao Z; Yin J; Zhong X; Zhao Z; Qiu W; Lu Z; Hu X
    BMC Neurol; 2015 Sep; 15():160. PubMed ID: 26337073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
    Leite MI; Coutinho E; Lana-Peixoto M; Apostolos S; Waters P; Sato D; Melamud L; Marta M; Graham A; Spillane J; Villa AM; Callegaro D; Santos E; da Silva AM; Jarius S; Howard R; Nakashima I; Giovannoni G; Buckley C; Hilton-Jones D; Vincent A; Palace J
    Neurology; 2012 May; 78(20):1601-7. PubMed ID: 22551731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.
    Ortiz Salas PA; Gaviria Carrillo M; Cortés Bernal GA; Moreno Medina K; Roa LF; Rodríguez Quintana JH
    Neurologia (Engl Ed); 2023 Sep; 38(7):504-510. PubMed ID: 35637138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromyelitis optica spectrum disorders: still evolving and broadening.
    Fujihara K
    Curr Opin Neurol; 2019 Jun; 32(3):385-394. PubMed ID: 30893099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and extensive spinal white matter involvement in neuromyelitis optica.
    Hayashida S; Masaki K; Yonekawa T; Suzuki SO; Hiwatashi A; Matsushita T; Watanabe M; Yamasaki R; Suenaga T; Iwaki T; Murai H; Kira JI
    Brain Pathol; 2017 May; 27(3):249-265. PubMed ID: 27082714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
    Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
    Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis.
    Kang H; Chen T; Li H; Xu Q; Cao S; Wei S
    J Neurol; 2017 Oct; 264(10):2130-2140. PubMed ID: 28879451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.